Editas Medicine, Inc Stock News

Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on W

Editas Medicine, Inc. (NASDAQ:EDIT ) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022 10:30 AM ET Company Participants Gilmore O'Neill - President and Chief Executive Of

Editas Medicine, Inc. (NASDAQ:EDIT ) 2022 Wells Fargo Healthcare Conference September 7, 2022 1:55 PM ET Company Participants Gilmore O'Neill - Chief Executive Officer Mark Shearman - Chief Scientific

CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following upcoming

Results from phase 1/2 BRILLIANCE study using EDIT-101 (Cas9 nuclease) for the treatment of patients with Leber Congenital Amaurosis 10 expected 2nd half of 2022. Results from the phase 1/2 RUBY study

GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.

The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positiv

Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.

Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.

Editas Medicine, Inc. (NASDAQ:EDIT ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Executive Chairman Gilmore O'Neill -

The company's top line really caught investors' eye.

The company's top line really caught investors' eye.

Editas (EDIT) delivered earnings and revenue surprises of 7.14% and 19.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team